China Lilang (01234) H2 2024 Earnings Call March 18, 2025 12:30 AM ET Moderator Good afternoon, investors. Thank you so much for your attendance to the twenty twenty four China Leilan Annual Result Investors Meeting. This is Angela from SPRG. The meeting is the form of both telephone online and off line. Investors using the online should have received before the event the PPT. If you have not received the slides, please contact the SVRG team. Please be reminded that the English channel is only for listening ...

Core Viewpoint - Travere Therapeutics has submitted a supplemental New Drug Application (sNDA) to the FDA for FILSPARI, aiming for it to be the first FDA-approved treatment for focal segmental glomerulosclerosis (FSGS), a rare kidney condition [1][2] Company Overview - Travere Therapeutics is focused on developing therapies for rare diseases, emphasizing the urgent need for effective treatment options for conditions like FSGS [2][8] - FILSPARI is currently approved for slowing kidney function decline in adults with IgA nephropathy and is a non-immunosuppressive oral medication [2][9] Clinical Studies - The sNDA submission is supported by results from the Phase 3 DUPLEX Study and the Phase 2 DUET Study, which are among the largest interventional studies in FSGS [1][6] - The DUPLEX Study achieved its interim endpoint with statistical significance at 36 weeks, showing significant proteinuria reduction and a lower rate of end-stage kidney disease compared to the active control [6][7] - The DUET Study demonstrated a greater than two-fold reduction in proteinuria compared to irbesartan, with a consistent safety profile across trials [7] Regulatory Process - The FDA has 60 days to determine whether to accept the sNDA for review, with an expected notice in the second quarter of 2025 [3] - The FDA has indicated that REMS monitoring for embryo-fetal toxicity is no longer necessary, and the company plans to submit a modification to the REMS [4] Disease Context - FSGS is a rare kidney disorder affecting over 40,000 patients in the U.S., characterized by progressive scarring of the kidney and leading to kidney failure [5] - There are currently no FDA-approved pharmacologic therapies for FSGS, highlighting the significance of FILSPARI's potential approval [5]

YPF (YPF) Q4 2024 Earnings Call March 07, 2025 09:00 AM ET Company Participants Margarita Chun - Investor Relations OfficerHoracio Marin - CEO & ChairmanMaximiliano Westen - Strategy, New Businesses and Controlling Vice PresidentFederico Barroetave - Chief Financial OfficerAndrés Cardona - DirectorDaniel Guardiola - Executive Director - Equity ResearchBruno Montanari - Executive Director - Equity ResearchTasso Vasconcellos - Equity ResearchLeonardo Marcondes - VP - Equity ResearchGuilherme Costa Martins - E ...

Core Argument - The New Civil Liberties Alliance (NCLA) filed an amicus curiae brief urging the Fifth Circuit to uphold a preliminary injunction against the enforcement of the Corporate Transparency Act (CTA), which they argue is unconstitutional and exceeds regulatory authority [1][3]. Summary by Sections Corporate Transparency Act (CTA) Overview - The CTA requires organizations incorporated under state law to submit detailed reports containing sensitive information to the Department of the Treasury, with civil or criminal penalties for non-compliance affecting over 30 million organizations nationwide [2]. Legal Arguments Against CTA - The government claims the CTA is authorized by the Constitution's Commerce Clause, but the NCLA argues that incorporation does not constitute economic activity, as it does not involve the production, consumption, or exchange of goods or services [3]. - The NCLA contends that the government's request to limit the injunction to only the corporate entities involved in the Texas case is flawed, as the Administrative Procedure Act allows for a nationwide injunction against the CTA [4]. NCLA's Position - NCLA emphasizes that regulating based solely on a corporation's status as a commercial actor would lead to boundless governmental power, undermining the concept of limited government [5].

Avantor (AVTR) Q4 2024 Earnings Call February 07, 2025 08:00 AM ET Company Participants Allison Hosak - Senior VP - Global CommunicationsMichael Stubblefield - President and CEOBrent Jones - EVP & CFOVijay Kumar - Senior Managing DirectorMadeline Mollman - Senior Associate - Equity ResearchTycho Peterson - Managing DirectorBrandon Couillard - Managing Director Conference Call Participants Michael Ryskin - AnalystDaniel Brennan - AnalystRachel Vatnsdal - AnalystLuke Sergott - AnalystPatrick Donnelly - Analys ...